Pictilisib (GDC-0941)

Name: Pictilisib (GDC-0941)
Brand: Selleck Chemicals
SKU: S1065
Rating: 5 (303 reviews)

For research use only.

Catalog No.S1065 Synonyms: RG7321

303 publications

Pictilisib (GDC-0941) Chemical Structure

Molecular Weight(MW): 513.64

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.

Selleck's Pictilisib (GDC-0941) has been cited by 303 publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2017, 23(11):1342-1351

PubMed: 29035366 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cell, 2013, 7;155(4):844-57.

PubMed: 24209622 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Nat Cell Biol, 2020, 22(3):289-296

PubMed: 32094692 ( click the link to review the publication )

Nat Commun, 2020, 8;11(1):2291

PubMed: 32385243 ( click the link to review the publication )

Nat Commun, 2020, 11(1):1290

PubMed: 32157087 ( click the link to review the publication )

Cell Syst, 2020, 20;10(5):384-396.e9

PubMed: 32437683 ( click the link to review the publication )

Cell Syst, 2020, 10(3):240-253

PubMed: 32191874 ( click the link to review the publication )

Cell Rep, 2020, 30(13):4584-4599

PubMed: 32234489 ( click the link to review the publication )

J Control Release, 2020, 318:98-108

PubMed: 31838203 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )
Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 8

PubMed: 32382996 ( click the link to review the publication )

Front Oncol, 2020, 1;10:393

PubMed: 32296637 ( click the link to review the publication )

Sci Rep, 2020, 4;10(1):7401

PubMed: 32366879 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Eur J Pharmacol, 2020, 873:172981

PubMed: 32014486 ( click the link to review the publication )

J Cell Biol, 2020, 219(2)

PubMed: 31914171 ( click the link to review the publication )

Oncotarget, 2020, 28;11(17):1493-1504

PubMed: 32391119 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5584-5599

PubMed: 31527310 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Cancer Res, 2019, 79(6):1138-1150

PubMed: 30679179 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(9):2835-2847

PubMed: 30670492 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2892-2908

PubMed: 31048499 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.216218

PubMed: 31471373 ( click the link to review the publication )

Int J Cancer, 2019, 145(3):817-829

PubMed: 30671946 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

MBio, 2019, 10(1)

PubMed: 30755508 ( click the link to review the publication )
Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(9):2004-2015

PubMed: 31059696 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):41

PubMed: 30691487 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):236

PubMed: 31164152 ( click the link to review the publication )

Cells, 2019, 8(2)

PubMed: 30795621 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2395-2409

PubMed: 31548239 ( click the link to review the publication )

J Transl Med, 2019, 17(1):431

PubMed: 31888636 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):431-442

PubMed: 30483742 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Pestic Biochem Physiol, 2019, 154:67-77

PubMed: 30765058 ( click the link to review the publication )

Contrast Media Mol Imaging, 2019, 2019:1760184

PubMed: 31787861 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(6)

PubMed: 31704709 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Blood, 2018, 10.1182/blood-2018-08-872465

PubMed: 30322870 ( click the link to review the publication )

Mol Cell, 2018, 71(6):1092-1104

PubMed: 30174291 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4945

PubMed: 30470748 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )
Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Clin Cancer Res, 2018, 15;24(6):1436-1447

PubMed: 29127119 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )

Oncogene, 2018, 37(10):1369-1385

PubMed: 29311642 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30545064 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):809

PubMed: 30042442 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):71

PubMed: 30237393 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):1881-1896

PubMed: 30132519 ( click the link to review the publication )

Proteomics, 2018, 18(23):e1800244

PubMed: 30267477 ( click the link to review the publication )
Invest New Drugs, 2018, 36(5):763-772

PubMed: 29504069 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

Prostate, 2018, 78(13):1013-1023

PubMed: 30133757 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):715-725

PubMed: 29901201 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0193849

PubMed: 29799846 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467326 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):611-618

PubMed: 28494242 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2249

PubMed: 29269732 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(18):5561-5572

PubMed: 28606920 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(41):5681-5694

PubMed: 28604746 ( click the link to review the publication )

Oncogene, 2017, 36(36):5110-5121

PubMed: 28481878 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )
Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0415

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Oncogenesis, 2017, 6(11):398

PubMed: 29184057 ( click the link to review the publication )

Cell Discov, 2017, 3:16054

PubMed: 28224045 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

J Immunol, 2017, 198(2):657-668

PubMed: 27940659 ( click the link to review the publication )

Sci Rep, 2017, 7(1):5519

PubMed: 28717217 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3964

PubMed: 28638122 ( click the link to review the publication )

Mol Pharmacol, 2017, 91(1):65-73

PubMed: 27821547 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(10):816-826

PubMed: 29099264 ( click the link to review the publication )

Biol Reprod, 2017, 97(5):671-687

PubMed: 29036279 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(8):722-734

PubMed: 28359246 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(2):3259-3273

PubMed: 27965462 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )
Oncotarget, 2017, 8(32):52877-52888

PubMed: 28881779 ( click the link to review the publication )

Oncotarget, 2017, 8(8):12558-12575

PubMed: 28147342 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Physiol Rep, 2017, 5(18)

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83052-83062

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 9(10):8870-8886

PubMed: 29507660 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1345-1356

PubMed: 27117832 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cell Rep, 2016, 15(12):2692-704

PubMed: 27292631 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27700986 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Oncogene, 2016, 35(27):3587-97

PubMed: 26549034 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1545-56

PubMed: 27196766 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1248-60

PubMed: 27197306 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):94-105

PubMed: 26637365 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3507-3519

PubMed: 27992857 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )
Sci Rep, 2016, 6:37213

PubMed: 27849011 ( click the link to review the publication )

PLoS Comput Biol, 2016, 12(4):e1004827

PubMed: 27035903 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )

Oncotarget, 2016, 7(28):44448-44461

PubMed: 27286446 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43124-43149

PubMed: 27281609 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82424-82439

PubMed: 27489350 ( click the link to review the publication )

Nat Commun, 2015, 6:7212

PubMed: 25998442 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Nat Commun, 2015, 6:8501

PubMed: 26442967 ( click the link to review the publication )

J Exp Med, 2015, 212(6):883-92

PubMed: 25987726 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(28):8638-43

PubMed: 26124089 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

Elife, 2015, 4:e10510

PubMed: 26523394 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(12):3115-3124

PubMed: 26302068 ( click the link to review the publication )

Sci Signal, 2015, 8(401):ra111

PubMed: 26535009 ( click the link to review the publication )

Sci Signal, 2015, 8(396):ra96

PubMed: 26420907 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1591

PubMed: 25590801 ( click the link to review the publication )
Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: 25292196 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

J Biol Chem, 2015, 290(35):21705-12

PubMed: 26152725 ( click the link to review the publication )

J Biol Chem, 2015, 290(40):24367-80

PubMed: 26294766 ( click the link to review the publication )

Proteomics, 2015, 15(2-3):327-39

PubMed: 25339196 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(3):402-11

PubMed: 25692408 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: 25327687 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: 25590338 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143357

PubMed: 26580203 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0122689

PubMed: 25837824 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9189-205

PubMed: 25826077 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015, 96(3):507-17

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43540-56

PubMed: 26498353 ( click the link to review the publication )

Oncotarget, 2015, 6(31):32089-103

PubMed: 26392332 ( click the link to review the publication )
Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(18):16488-506

PubMed: 26029997 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33091-105

PubMed: 26384305 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(47):16826-9

PubMed: 25385636 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4597-4611

PubMed: 25183785 ( click the link to review the publication )

Oncogene, 2014, 33(26):3422-31

PubMed: 23912457 ( click the link to review the publication )

Oncogene, 2014, 33(8):966-76

PubMed: 23474757 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Oncogene, 2014, 33(23):3043-53

PubMed: 23893244 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(2):147-57

PubMed: 24709422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-37

PubMed: 25520871 ( click the link to review the publication )

J Immunol, 2014, 193(6):3036-44

PubMed: 25092892 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )
PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84746

PubMed: 24404189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Mol Med Rep, 2014, 9(1):83-90

PubMed: 24213221 ( click the link to review the publication )

Anticancer Drugs, 2014, 25(2):183-8

PubMed: 24100276 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7936-44

PubMed: 25277205 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6512-25

PubMed: 25156567 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Harvard University, 2014,

PubMed: ( click the link to review the publication )

Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )

Blood, 2013, 121(12):2274-84

PubMed: 23341541 ( click the link to review the publication )

J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Leukemia, 2013, 27(11):2118-28

PubMed: 23535559 ( click the link to review the publication )

Cancer Res, 2013, 73(3):1190-200

PubMed: 23204226 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )
Oncogene, 2013, 33(9):1190-7

PubMed: 23435426 ( click the link to review the publication )

Sci Signal, 2013, 6(288):ra68

PubMed: 23943608 ( click the link to review the publication )

Sci Signal, 2013, 6(268):ra20

PubMed: 23532334 ( click the link to review the publication )

PLoS Genet, 2013, 9(2):e1003253

PubMed: 23459592 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2950-61

PubMed: 24107445 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1099-108

PubMed: 23345407 ( click the link to review the publication )

Cancer Sci, 2013, 104(8):1027-32

PubMed: 23710822 ( click the link to review the publication )

J Biol Chem, 2013, 288(21):14698-708

PubMed: 23585567 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cancer Med, 2013, 2(1):76-85

PubMed: 24133630 ( click the link to review the publication )

FEBS Lett, 2013, 587(1):5-16

PubMed: 23178716 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66306

PubMed: 23824914 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):557-61

PubMed: 23665330 ( click the link to review the publication )

Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2502-14

PubMed: 22351686 ( click the link to review the publication )

Clin Cancer Res, 2012, 19(3):657-67

PubMed: 23251002 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e400

PubMed: 23059819 ( click the link to review the publication )
J Cell Sci, 2012, 125(Pt 5):1259-73

PubMed: 22399812 ( click the link to review the publication )

Cancer Sci, 2012, 103(9):1665-71

PubMed: 22703543 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(12):2210-6

PubMed: 22974639 ( click the link to review the publication )

J Leukoc Biol, 2012, 92(1):219-31

PubMed: 22544939 ( click the link to review the publication )

Mol Cell Biol, 2012, 32(22):4674-83

PubMed: 22988297 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Oncotarget, 2012, 3(8):811-23

PubMed: 22885370 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(8):2260-9

PubMed: 21220474 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(37):E699-708

PubMed: 21876152 ( click the link to review the publication )

Cancer Res, 2011, 71(7):2750-60

PubMed: 21317224 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(2):495-503

PubMed: 21048785 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Thyroid, 2010, 20(7):689-95

PubMed: 20578898 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)
3 nM	3 nM	33 nM	75 nM	0.58 μM(Ki app)

In vitro

GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. ^[1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. ^[2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. ^[3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Sf9	NY\USGxCU2mwYYPlJGF{e2G7		NXvNVVRQOSCq	NXq0OIxGTE2VTx?=	M3jDeWlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyZHXseIEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDjc4V5eHKnc4PpcocheDh3YXzwbIEhf2m2aDDJR\|UxKG:oIECuNFA{KM7:TR?=	NF\DXpAyQDd3NE[1OC=>
Sf9	NXe2NVk4U2mwYYPlJGF{e2G7		MX2xJIg>	NVrFemxqTE2VTx?=	NXjUbWNrUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKEhzMES3MXIhdXW2YX70JIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjhJJdqfGhiSVO1NEBw\iByLkCwN{DPxE1?	M4HKT\|E5PzV2NkW0
Sf9	NF7xd\|hMcW6jc3WgRZN{[Xl?		MYexJIg>	MYXEUXNQ	M1XPcGlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyYnX0ZUBGPTR3LVugcZV1[W62IHX4dJJme3OnZDDpckBU\jliY3XscJMh[2:neIDy[ZN{cW6pIIC4OYFteGijIIfpeIghUUN3MDDv[kAxNjByMzFOwG0>	NWjENndvOTh5NUS2OVQ>
Sf9	MlmyT4lv[XOnIFHzd4F6		M37mcFEhcA>?	M4\lcWROW09?	NUjGNY84UW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZ49mgHC{ZYPzbY5oKHB6NXHsdIhiKHerdHigTWM2OCCxZjCwMlA{OyEQvF2=	MWGxPFc2PDZ3NB?=
Sf9	NFm5W\|VMcW6jc3WgRZN{[Xl?		M3zVTlEhcA>?	MmLESG1UVw>?	NGfiVlRKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2sheDFzMHHsdIhiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZ49mgHC{ZYPzbY5oKHB6NXHsdIhi	MYGxPFc2PDZ3NB?=
MDA-MB-361	NUHPToZsTnWwY4Tpc44hSXO\|YYm=		NYLpSJRIOiCq	Mn74SG1UVw>?	MXXJcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKE2GQT3NRk0{PjFiY3XscJMhf2m2aDDQTWs{S0FiRUW0OU1MKG23dHH0bY9vKHerdHigTWM2OCCxZjCwMlAzQCEQvF2=	NUHhcGZVOTh5NUS2OVQ>
PC3	M3m1PGZ2dmO2aX;uJGF{e2G7		NYfqfJRXOiCq	M{e4b2ROW09?	NVrlV5BLUW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDpckBRXEWQLX71cIwhcHWvYX6gVGM{KGOnbHzzJJdqfGhiSVO1NEBw\iByLkCzO{DPxE1?	MmPkNVg4PTR4NUS=
U87MG	NXTSVXN4TnWwY4Tpc44hSXO\|YYm=		MWKyJIg>	NV\pOop[TE2VTx?=	NYLDfmJQUW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDpckBRXEWQLX71cIwhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDJR\|UxKG:oIECuNFQ3KM7:TR?=	NEnyfJQyQDd3NE[1OC=>
MDA-MB-361	Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmfUPVYhcA>?	MnnQSG1UVw>?	MmjCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOzZzIHPlcIx{KHerdHigVGlMO0ODIFW1OFUuUyCvdYTheIlwdiC5aYToJGlEPTBib3[gNE44OiEQvF2=	M4joVVE5PzV2NkW0
A2780	NYeyeYRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnjXPVYhcA>?	Mor1SG1UVw>?	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF{N{iwJINmdGy\|IIfpeIghWEmNM1PBJIFv\CCSVFXOJI12fGG2aX;uJJdqfGhiSVO1NEBw\iByLkG0JO69VQ>?	MoDjNVg4PTR4NUS=
PC3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWnLPI9HQTZiaB?=	M2LWSWROW09?	MWXJR\|UxRTBwMkig{txO	MoHwNVg4PTR4NUS=
U87MG	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHvOPJg6PiCq	NVLOXWxqTE2VTx?=	NE\UPZpKSzVyPUCuPVUh\|ryP	NWq1XGJ[OTh5NUS2OVQ>
Sf9	NUDnSZdIU2mwYYPlJGF{e2G7		MoLJN\|AhdWmw	NIjafmlFVVOR	NXjmRVNzUW6qaXLpeIlwdiCxZjDoeY1idiCSSUPL[4FudWFiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJIFud3WwdDDv[kBCXFBiY3;ud5Vu\WRid3n0bEBKSzVyIH;mJFAvODR{IN88US=>	M33RSlIzPTR6M{Sy
RAW 264.7	M1jET2tqdmG\|ZTDBd5NigQ>?		MmLCPVAhdWmw	M{n2dmROW09?	NHrQcoFKdmirYnn0bY9vKG:oIHj1cYFvKFCLM1vnZY1u[SCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDS2SgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjJ7ODFOwG0>	NULGUGs{OjJ3NEizOFI>
Sf9	NHPkSlNMcW6jc3WgRZN{[Xl?		M3T5dVEhcA>?		NX3STVE{UW6qaXLpeIlwdiCxZjDHV3Qu\nW\|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2KndHGg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPGPUBk\WyuczD3bZRpKEmFNUCgc4YhOC5yMUeg{txO	M{XrUFI{PTRyNkS1
Sf9	NX;5Umw1U2mwYYPlJGF{e2G7		NHKyNlcyKGh?		MVrJcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPL[IVtfGFiZYjwdoV{e2Wm	NGjZZoEzOzV2ME[0OS=>
Sf9	M3Oz[mtqdmG\|ZTDBd5NigQ>?		NGnrXlkyKGh?		NWPDUYM{UW6qaXLpeIlwdiCxZjDHV3Qu\nW\|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2ejbX3hJIV5eHKnc4Pl[C=>	MV:yN\|U1ODZ2NR?=
Sf9	NYLZRZY4U2mwYYPlJGF{e2G7		M4[3c\|EhcA>?		M3jKe2lvcGmkaYTpc44hd2ZiR2PUMYZ2e2WmIHj1cYFvKHKnY3;tZolv[W62IGDJN2tidHCqYTDlfJBz\XO\|ZXS=	M164clI{PTRyNkS1
SKOV3	M3jIR2tqdmG\|ZTDBd5NigQ>?	NIPrdZQyKM7:TR?=	NW\ZPWNuOSCq	NV\3dos6TE2VTx?=	NWqxdZJZUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbh?=	MV6yN\|M3ODN2OB?=
MCF7	M3rlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;ZRWZlOSEQvF2=	M2\Eflk3KGh?	M3fMPWROW09?	MnnaS2k2OD1yLkC3NFIh\|ryP	M2SxclI{OzZyM{S4
SKOV3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX:xJO69VQ>?	NIfJSmc6PiCq	NEPyUZRFVVOR	MYfHTVUxRTBwMUS3OkDPxE1?	M3LYVlI{OzZyM{S4
PC3	NXjKfnNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV;ndHVOPzJiaB?=	M4HuUWROW09?	MkH4TWM2OD1yLkK4JO69VQ>?	M4LNbFIyQThzN{G0
MCF7.1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3j3NVczKGh?	MV3EUXNQ	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkeuNUBk\WyuczDlfJBz\XO\|aX7nJGhGWjJiZ3Xu[UB4cXSqIFnDOVAhd2ZiMD6yPEDPxE1?	MkmxNlE6QDF5MUS=
MCF7-neo/Her2	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXi3NkBp	MXPEUXNQ	MkGwTWM2OD1yLkK5JO69VQ>?	NU\vOWRMOjN4NkK5NFM>
MCF7-neo/Her2	MUjLbY5ie2ViQYPzZZk>				MWjJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdiCjdDDTOFc{KHerdHigTWM2OCCxZjCwMlAxPyEQvF2=	MVqyN\|Y3OjlyMx?=
PC3	NH:yfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M17nPFczKGh?	MY\EUXNQ	NXzGOpRqTUN3ME2wMlM1KM7:TR?=	NXX2OINqOjF7OEW2N\|k>
MCF7.1	MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFHNPYw4OiCq	MXXEUXNQ	NXr6fWQ5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4NjFiY3XscJMh\XiycnXzd4lv\yCSSUPLZYxxcGFibYX0ZY51KHerdHigSWM2OCCxZjCwMlM6KM7:TR?=	Mme1NlE6QDV4M{m=
PC3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVr1V\|NFPzJiaB?=	NELqRZRFVVOR	M1P5NGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy\|IHTl[olkcWWwdDDpckBRXEWQIIfpeIghUUN3MDDv[kAxNjN7IN88US=>	M{foNVIxODVyNk[5
MCF7.1	NXfyOWVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYG3NkBp	NEHP[5VFVVOR	MlP0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3MlEh[2WubIOg[ZhxemW\|c3nu[{BRUTONYXzwbIEhdXW2YX70JJdqfGhiSVO1NEBw\iByLkO0JO69VQ>?	NXzpUGlmOjByNUC2Olk>
MCF7.1	M3fXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXHn[Hk{PzJiaB?=		MWHFR\|UxRTBwN{Kg{txO	MW[yNFM1PjZ3Nh?=
NCI-H1975	MkDUR5l1d3SxeHnjJGF{e2G7		MWm3NkBp		MUDJR\|UxRTBwMkeg{txO	MX[yN\|A2QTV2NR?=
H460	MlOzR5l1d3SxeHnjJGF{e2G7		M3i4SlczKGh?		MX\JR\|UxRTBwOEeg{txO	NGm3UI0zOzB3OUW0OS=>
HT-29	MoTwR5l1d3SxeHnjJGF{e2G7		NXTmfYx6PzJiaB?=		M3zkcmlEPTB;MD62OkDPxE1?	MonuNlMxPTl3NEW=
HepG2	NV3afIJoS3m2b4TvfIlkKEG\|c3H5		NXm1Z\|lTPzJiaB?=		MlLBTWM2OD1zIN88US=>	NH\1VXkzOzB3OUW0OS=>
SGC7901	MYLDfZRwfG:6aXOgRZN{[Xl?		MkHCO\|IhcA>?		NVP4RlVtUUN3ME2xMlgh\|ryP	M1rOXFI{ODV7NUS1
NCI-H226	MlTQR5l1d3SxeHnjJGF{e2G7		MnHTO\|IhcA>?		NFTrdGhKSzVyPUKuPUDPxE1?	M{O1R\|I{ODV7NUS1
A549	NVzwcZBNS3m2b4TvfIlkKEG\|c3H5		NFLV[lA4OiCq		MkPuTWM2OD14Lkmg{txO	M4XBb\|I{ODV7NUS1
U87MG	M1\VSGN6fG:2b4jpZ{BCe3OjeR?=		NGnNeYc4OiCq		Mnj5TWM2OD15Lke3JO69VQ>?	Mn7mNlMxPTl3NEW=
HBC4	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vOTYxw\0eLNUC9MVYvODNiTR?=	NIjYdWszOjN\|NkK0Oi=>
BSY1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXte5dtd2eJSUWwQU03NjlyIF2=	M1XjTFIzOzN4MkS2
HBC5	NIrtN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rLcoxw\0eLNUC9MVYvPjBiTR?=	MXmyNlM{PjJ2Nh?=
MCF7	M3W0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HzO4xw\0eLNUC9MVcvOzNiTR?=	M4DaOFIzOzN4MkS2
MDA-MB-231	M{CzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTsc4dIUTVyPT21MlQ3KE1?	NHHmS5AzOjN\|NkK0Oi=>
U251	MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvsc4dIUTVyPT21MlUxKE1?	MVeyNlM{PjJ2Nh?=
SF268	M3;1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfsc4dIUTVyPT21MlM6KE1?	M3HmUVIzOzN4MkS2
SF295	NUSxTGc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFi0[XJtd2eJSUWwQU03NjN5IF2=	NU\lV2ZNOjJ\|M{[yOFY>
SF539	NH\UfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnYcI9oT0l3ME2tOk42OCCP	NFfHN4ozOjN\|NkK0Oi=>
SNB75	NHr6OJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TIO4xw\0eLNUC9MVcvOTBiTR?=	NEK2O4czOjN\|NkK0Oi=>
SNB78	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXsc4dIUTVyPT22MlUzKE1?	NF3YeFczOjN\|NkK0Oi=>
HCC2998	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PUU4xw\0eLNUC9MVYvOjliTR?=	Ml7mNlI{OzZ{NE[=
KM12	NG[3RlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHsc4dIUTVyPT21Mlc3KE1?	NXnxNWxMOjJ\|M{[yOFY>
HT-29	M2rCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\acI9oT0l3ME2tOk4{OCCP	Ml7qNlI{OzZ{NE[=
HCT15	NGG0emRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV[yRZQ2dG:pR1m1NF0uPi5zMjDN	NY[3OZg5OjJ\|M{[yOFY>
HCT116	NHfBbG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkD6cI9oT0l3ME2tOU45PyCP	NH\EZ3AzOjN\|NkK0Oi=>
NCI-H23	NFzLPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPkcI9oT0l3ME2tOU44OyCP	Mnz6NlI{OzZ{NE[=
NCI-H226	M3PYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUH6NlZVdG:pR1m1NF0uPi5{MTDN	NIizeZQzOjN\|NkK0Oi=>
NCI-H522	M3W4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofEcI9oT0l3ME2tOk42QCCP	NHvEWIczOjN\|NkK0Oi=>
NCI-H483	NVnlcYY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHicI9oT0l3ME2tOk42PiCP	MXOyNlM{PjJ2Nh?=
A549	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoT5cI9oT0l3ME2tOk4yPSCP	MWeyNlM{PjJ2Nh?=
DMS273	NVXRW4RnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2WxW4xw\0eLNUC9MVYvPDNiTR?=	MnfSNlI{OzZ{NE[=
DMS114	M4n4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjsc4dIUTVyPT21MlkzKE1?	NFPkUXgzOjN\|NkK0Oi=>
LOXIMVI	NVi2UFBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3izeoxw\0eLNUC9MVYvOjliTR?=	NX7qUZBYOjJ\|M{[yOFY>
OVCAR3	NXXCbVdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPZS4VvdG:pR1m1NF0uPi55MTDN	NXXmdGUzOjJ\|M{[yOFY>
OVCAR4	MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLWcI9oT0l3ME2tOU44PiCP	NIPOc4czOjN\|NkK0Oi=>
OVCAR5	M3rqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPqTZk3dG:pR1m1NF0uPi5{NjDN	NVfqXXVSOjJ\|M{[yOFY>
OVCAR8	NULmOnJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\WSYRRdG:pR1m1NF0uPS55MzDN	MlTDNlI{OzZ{NE[=
SKOV3	NV7reYJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjsc4dIUTVyPT22MlUzKE1?	MXGyNlM{PjJ2Nh?=
RXF631L	M4LCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPsc4dIUTVyPT22Mlg5KE1?	NGnVXlQzOjN\|NkK0Oi=>
ACHN	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HFWIxw\0eLNUC9MVYvODdiTR?=	M13BPFIzOzN4MkS2
St-4	NGjRVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLPcI9oT0l3ME2tOU42PiCP	M331XVIzOzN4MkS2
MKN1	M1HTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTsc4dIUTVyPT23MlA5KE1?	Mn[zNlI{OzZ{NE[=
MKN7	NFjTOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnSd5Ftd2eJSUWwQU03NjVyIF2=	NVrub49rOjJ\|M{[yOFY>
MKN28	MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7WSHBtd2eJSUWwQU02NjV{IF2=	NUHzTml7OjJ\|M{[yOFY>
MKN45	NWHMSJZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHZelh1dG:pR1m1NF0uPi53NTDN	NGLKWGszOjN\|NkK0Oi=>
MKN74	MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3ywR4xw\0eLNUC9MVYvODJiTR?=	NFrWO2ozOjN\|NkK0Oi=>
DU145	NEjiWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3sc4dIUTVyPT21Mlg2KE1?	MYKyNlM{PjJ2Nh?=
PC3	NX;CR2VCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\ZR3Btd2eJSUWwQU03NjZ4IF2=	NITSbFUzOjN\|NkK0Oi=>
ES5	M2\Xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkL4TWM2OD13MD6yNUBvVQ>?	Mnz2V2FPT0WU
HH	Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjaTWM2OD1zMUGuNFghdk1?	NEX3PHpUSU6JRWK=
MHH-PREB-1	NXnQfGdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTFzND6zJI5O	MYnTRW5ITVJ?
NCI-H1770	MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTF{Mz64OkBvVQ>?	MW\TRW5ITVJ?
HuO9	MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonpTWM2OD1{ME[uNFIhdk1?	MYTTRW5ITVJ?
HAL-01	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;jSGlEPTB;MkC2Mlc{KG6P	MnzhV2FPT0WU
NOS-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTJzMT64NkBvVQ>?	NH3RPXVUSU6JRWK=
HGC-27	M{HBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGe2R4lKSzVyPUKxNk42PyCwTR?=	M4LXNnNCVkeHUh?=
NB69	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\n[WlEPTB;MkS1MlI4KG6P	MULTRW5ITVJ?
RS4-11	MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTJ4MT63OkBvVQ>?	Mni2V2FPT0WU
DOK	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TROWlEPTB;M{CxMlchdk1?	MX3TRW5ITVJ?
LB2241-RCC	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXmO5VmUUN3ME2zNFMvQDRibl2=	MnzaV2FPT0WU
NCI-H1623	NGPsT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rrbWlEPTB;M{C0MlA5KG6P	MUnTRW5ITVJ?
YH-13	NFW1OVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH[zSVJKSzVyPUOwOE4{OiCwTR?=	NYLw[WdtW0GQR1XS
BPH-1	NEjqVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLNU\|c2UUN3ME2zNVQhdk1?	MVPTRW5ITVJ?
AN3-CA	NX3lRoJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXFTWM2OD1\|NECuN\|chdk1?	M{\5THNCVkeHUh?=
ES7	NE\4bnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjrdndKSzVyPUO0NU46QSCwTR?=	MVfTRW5ITVJ?
MDA-MB-175-VII	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnZTWM2OD1\|NUKuPVIhdk1?	M4XDe3NCVkeHUh?=
GAMG	M2W1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLx[HBKSzVyPUO3NE45PSCwTR?=	MYPTRW5ITVJ?
CHL-1	NWrIUnlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTN5OD62OUBvVQ>?	M2PZc3NCVkeHUh?=
NB7	NYPh[JJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\hT2kxUUN3ME2zPFkvQDNibl2=	Mm\GV2FPT0WU
MFE-280	NG\INZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXKT21KSzVyPUSxPE4zKG6P	NF7VPVBUSU6JRWK=
HL-60	MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7CTWM2OD12MkWuO\|Uhdk1?	NXXZRpR3W0GQR1XS
GCIY	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\nSolKSzVyPUSzN{45KG6P	M1TlcHNCVkeHUh?=
MDA-MB-361	Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLtTWM2OD12M{muNVMhdk1?	MVTTRW5ITVJ?
LXF-289	NWnRbWk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHmTWM2OD12NEiuNlchdk1?	Mn\mV2FPT0WU
NBsusSR	NYTmU4x7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfxTWM2OD12OEiuPFUhdk1?	NIfLZWJUSU6JRWK=
KU-19-19	NXLtZnJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XyOGlEPTB;NUG2MlA4KG6P	M4T5OXNCVkeHUh?=
A204	NWDnV\|liT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrxUWRKSzVyPUWyNk4{OyCwTR?=	NXzD[XNEW0GQR1XS
LB1047-RCC	Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvPS4ZKSzVyPUWyNk46OyCwTR?=	MUDTRW5ITVJ?
COLO-684	NITzRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzIelNQUUN3ME21NlMvOTFibl2=	NF\FfGpUSU6JRWK=
PA-1	Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LjT2lEPTB;NUOyMlQyKG6P	NIC5SoFUSU6JRWK=
MG-63	M3nIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3q4fmlEPTB;NUSxMlEyKG6P	MliyV2FPT0WU
BHT-101	NV;hdWJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TZWmlEPTB;NUS0Mlk1KG6P	MmXMV2FPT0WU
NKM-1	NHzN[\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mli5TWM2OD13OUOuNFkhdk1?	MmjKV2FPT0WU
T47D	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLLTWM2OD13OUeuOVYhdk1?	MmTqV2FPT0WU
MOLT-4	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV61VXczUUN3ME22NlMvPjJibl2=	NGP1[I9USU6JRWK=
IGROV-1	M4XqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\wTWM2OD14M{SuN\|Ehdk1?	MkDSV2FPT0WU
ES4	NEfVNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTZ\|OT61OEBvVQ>?	NYHPeGJpW0GQR1XS
HuO-3N1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTZ2Mj6zPEBvVQ>?	MnTDV2FPT0WU
NEC8	M3G3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHPOIRKSzVyPU[1N{42PyCwTR?=	MWDTRW5ITVJ?
HO-1-N-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTZ3OT6xO{BvVQ>?	MXzTRW5ITVJ?
EPCL-272H	NV\PZ2pyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfQelE6UUN3ME22PFcvOjFibl2=	NVLlWoQxW0GQR1XS
D-263MG	NYjwXWZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1i4SGlEPTB;N{G4MlEhdk1?	NVzMNphyW0GQR1XS
MV-4-11	MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHDfFFKSzVyPUeyOE4{OSCwTR?=	NWfafph{W0GQR1XS
SK-NEP-1	NXf5cYxjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPPcGpKSzVyPUeyOU46PCCwTR?=	MYPTRW5ITVJ?
SW872	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTd{Nz64PUBvVQ>?	NIfQc3VUSU6JRWK=
P30-OHK	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1z1UmlEPTB;N{OwMlcyKG6P	MWfTRW5ITVJ?
OMC-1	NHL1OG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PSfGlEPTB;N{WxMlA6KG6P	MoTVV2FPT0WU
LoVo	NIezcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vKeGlEPTB;N{e3Mlkhdk1?	M3TPUnNCVkeHUh?=
LNCaP-Clone-FGC	NF3URmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3G1RWlEPTB;N{m2MlM1KG6P	NG\mTpVUSU6JRWK=
L-363	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPsd3NKSzVyPUe5PE41OiCwTR?=	NVPMb2VTW0GQR1XS
ES8	NFPwNnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Hab2lEPTB;OEGwMlUzKG6P	MV;TRW5ITVJ?
697	NXTE[oIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrE[GtKSzVyPUizNU42PSCwTR?=	NUnXWVhpW0GQR1XS
HSC-3	M1;pSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmO2TWM2OD16M{muOVQhdk1?	M1LPeXNCVkeHUh?=
H4	Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTLXGVRUUN3ME24OVAvQDVibl2=	MX;TRW5ITVJ?
QIMR-WIL	M3e5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TVbWlEPTB;OE[1MlIhdk1?	NWrrc4tTW0GQR1XS
OAW-42	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHNVoFKSzVyPUi3Nk4yQSCwTR?=	MWLTRW5ITVJ?
MCF7	NXrEbWxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTh7OD61PUBvVQ>?	NFPXUFhUSU6JRWK=
SCC-25	MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjVcGhKSzVyPUmxOE4yQSCwTR?=	MVTTRW5ITVJ?
NCI-H1563	NWrRb5oyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTlzNT65PUBvVQ>?	NFraTI5USU6JRWK=
OVCAR-5	NV;S[mZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTl2MD6xO{BvVQ>?	MlXpV2FPT0WU
HDLM-2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTl2OT6yJI5O	NHfBclNUSU6JRWK=
NB5	Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPCTWM2OD17NU[uOkBvVQ>?	NFLjXGlUSU6JRWK=
NCI-H292	NWftenB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLxPYJKSzVyPUm3OE4{OiCwTR?=	NFnke2NUSU6JRWK=
A101D	NF3IUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLyTWM2OD17OUCuNVkhdk1?	MULTRW5ITVJ?
NCI-H1648	M3i4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jwPGlEPTB;OUm4MlUyKG6P	M3Xsc3NCVkeHUh?=
EKVX	M4e2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\UUYxKSzVyPUGuNFEzQSEQvF2=	M3PtSHNCVkeHUh?=
SW1710	NUK2OG1CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTFwMESyN\|Mh\|ryP	MUHTRW5ITVJ?
WM-115	M4XEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHu0SHZKSzVyPUGuNFY3PTZizszN	NULNc4lDW0GQR1XS
CAL-54	MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\KTWM2OD1zLkC3NFgyKM7:TR?=	M3TqNXNCVkeHUh?=
TGBC24TKB	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXQTWM2OD1zLkC4NFQ2KM7:TR?=	MmSzV2FPT0WU
NCI-H520	M2DSVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDleGxKSzVyPUGuNFg6PjdizszN	NIO0dppUSU6JRWK=
D-423MG	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mme0TWM2OD1zLkC5PVYzKM7:TR?=	NVrkN\|hSW0GQR1XS
BFTC-905	NFyyb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjmeIJKSzVyPUGuNVM1PDlizszN	MWTTRW5ITVJ?
HT	NIDzSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\j[pRKSzVyPUGuNVM1PzhizszN	M1PLUXNCVkeHUh?=
CTB-1	MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV[xWVZ2UUN3ME2xMlE1Ojl\|IN88US=>	M{PWSnNCVkeHUh?=
Hs-578-T	Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHrBN4FKSzVyPUGuNVk2PjVizszN	NE\Y[phUSU6JRWK=
HuH-7	NI[1RVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETxcFhKSzVyPUGuNlA6PDlizszN	MoTqV2FPT0WU
LB996-RCC	M3LFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TjUWlEPTB;MT6yNlE4PyEQvF2=	NFz5PWFUSU6JRWK=
KYSE-270	NW[2S2NOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHz3[mpKSzVyPUGuNlk4OzRizszN	M{DE[nNCVkeHUh?=
A4-Fuk	M165[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHW5T4xKSzVyPUGuNlk6QTNizszN	NFXQVY5USU6JRWK=
A498	Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTFwM{C0O\|Qh\|ryP	M1jFWXNCVkeHUh?=
SK-MEL-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvIVmVKSzVyPUGuN\|A3PzlizszN	NIjDWIdUSU6JRWK=
AU565	MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXGXXBKSzVyPUGuN\|E5PjNizszN	NVjQTlFIW0GQR1XS
Saos-2	NECzR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvtb29KSzVyPUGuN\|MzODVizszN	NWLwO3d2W0GQR1XS
A549	NVrnfoM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTFwM{m5O{DPxE1?	MWXTRW5ITVJ?
BFTC-909	MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PmTGlEPTB;MT60N\|MxPSEQvF2=	MWnTRW5ITVJ?
MDA-MB-415	MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nyXWlEPTB;MT60PFY6OiEQvF2=	MV\TRW5ITVJ?
639-V	NHmzcGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzsS\|JWUUN3ME2xMlUxOjR3IN88US=>	NH\wOJRUSU6JRWK=
A704	NXXHOIdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTFwNUC3PFUh\|ryP	NGXKT2tUSU6JRWK=
PANC-03-27	NES5e4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\jTWM2OD1zLkWxOFA5KM7:TR?=	MV7TRW5ITVJ?
SK-MEL-28	MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33icGlEPTB;MT61OlA5PSEQvF2=	MkfTV2FPT0WU
Ramos-2G6-4C10	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWi1Z3ZZUUN3ME2xMlYxPzR4IN88US=>	NGjYRoNUSU6JRWK=
HuP-T4	Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTFwNkC3O\|gh\|ryP	MXXTRW5ITVJ?
VA-ES-BJ	MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\oV2lEPTB;MT62NVI4KM7:TR?=	MW\TRW5ITVJ?
EFM-19	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33vPWlEPTB;MT62NVgyKM7:TR?=	NWXzUpRGW0GQR1XS
G-401	Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTFwNkKxOlQh\|ryP	NYjxRo5sW0GQR1XS
D-566MG	MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjkTWM2OD1zLk[yOVMh\|ryP	NH;rcGhUSU6JRWK=
JVM-3	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTFwNkS4O\|Uh\|ryP	MoDHV2FPT0WU
TK10	M4rWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPScotKSzVyPUGuOlcxQDNizszN	NUfhOG9WW0GQR1XS
BT-20	Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrRTWM2OD1zLk[4PVAzKM7:TR?=	NVHMdHVyW0GQR1XS
EGI-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LR[WlEPTB;MT64OFcxOSEQvF2=	NVuzTXJPW0GQR1XS
EW-16	M4LVW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XxXmlEPTB;MT64OVE5OiEQvF2=	NHfLVnJUSU6JRWK=
NCI-H2228	MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPjTWM2OD1zLki1NlA{KM7:TR?=	MV;TRW5ITVJ?
BB49-HNC	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXqTWM2OD1zLki4OlkzKM7:TR?=	NYr6NXFwW0GQR1XS
G-402	M1jscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml[wTWM2OD1zLki5O\|k4KM7:TR?=	MUnTRW5ITVJ?
NCI-H526	M4TOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3sNHBKSzVyPUGuPVE{QSEQvF2=	M{XNZ3NCVkeHUh?=
ME-180	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjCN4I6UUN3ME2xMlk{PDd5IN88US=>	M{[2RnNCVkeHUh?=
PFSK-1	MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPYWG04UUN3ME2xMlk1PDV6IN88US=>	MYfTRW5ITVJ?
TYK-nu	NUXaNWxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;w[Gl6UUN3ME2xMlk2QDJ\|IN88US=>	MlTxV2FPT0WU
HOS	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTFwOUe5OFgh\|ryP	NIjFcmdUSU6JRWK=
T98G	MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7GS\|ROUUN3ME2xMlk6ODB4IN88US=>	MV\TRW5ITVJ?
SK-MES-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTJwMEGzN\|Ih\|ryP	MX3TRW5ITVJ?
SNB75	NVnvZ4pmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHhWo1uUUN3ME2yMlAyPTRzIN88US=>	NHi3V\|BUSU6JRWK=
LAMA-84	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nmO2lEPTB;Mj6wNlY5QSEQvF2=	MV7TRW5ITVJ?
CAL-39	MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTJwMEOyPEDPxE1?	MUfTRW5ITVJ?
LOXIMVI	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTJwMESwPFQh\|ryP	NH\DcJdUSU6JRWK=
NH-12	M3KwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrCUoNKSzVyPUKuNFU1OjRizszN	M4\uU3NCVkeHUh?=
NCI-H1048	M4nFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrDdo5tUUN3ME2yMlExPTJizszN	NXfEfVlMW0GQR1XS
KS-1	Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXxUo1KSzVyPUKuNVExODFizszN	NVvoNpp2W0GQR1XS
NCI-N87	NXLqNFhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M370OGlEPTB;Mj6xN\|M5PCEQvF2=	NHXvWmZUSU6JRWK=
CHP-212	NHLhVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYr4N2NqUUN3ME2yMlE5PDR{IN88US=>	NIrWdXRUSU6JRWK=
HCC1419	NV;XboJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rXfWlEPTB;Mj6yNVEyPSEQvF2=	NH;tem1USU6JRWK=
ES1	NYrBU217T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrIZncxUUN3ME2yMlIyOzJ4IN88US=>	MUPTRW5ITVJ?
NCI-H2030	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mle5TWM2OD1{LkK0NVI{KM7:TR?=	MUTTRW5ITVJ?
EW-22	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTBTWM2OD1{LkK1NFY4KM7:TR?=	NX\MSZpJW0GQR1XS
A431	MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTJwMkezOVQh\|ryP	MlLxV2FPT0WU
SF126	NWnxOXJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTJwM{C2NlUh\|ryP	M2fXVXNCVkeHUh?=
SF295	MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLjPIRKSzVyPUKuN\|E2OjRizszN	MVXTRW5ITVJ?
D-502MG	NYTrbFd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPhTWM2OD1{LkOyOFYyKM7:TR?=	NUjOUnZbW0GQR1XS
HCC2157	NHG3TIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3T0R2lEPTB;Mj6zNlkzPyEQvF2=	NYDjW4VFW0GQR1XS
D-283MED	MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mor0TWM2OD1{LkO1PVI3KM7:TR?=	NWm1fmhZW0GQR1XS
SNU-423	MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV[4WWlxUUN3ME2yMlQxOTdzIN88US=>	M1zJdHNCVkeHUh?=
SK-LU-1	Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPCXJBKSzVyPUKuOFQ2QDZizszN	MUPTRW5ITVJ?
22RV1	NVPSNHFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEK0bFdKSzVyPUKuOFU3OTdizszN	Ml7mV2FPT0WU
SW1088	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;OTWM2OD1{LkS5NlE{KM7:TR?=	M2TkWHNCVkeHUh?=
HT-3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTJwNEmyOVkh\|ryP	NUnGZYYyW0GQR1XS
NCI-H1666	M{XnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTJwNUGxNFQh\|ryP	NFTUOFlUSU6JRWK=
EM-2	M1\QeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPsTWM2OD1{LkWxNVY6KM7:TR?=	M2LucHNCVkeHUh?=
SNU-449	NXjzOXc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTnZpR5UUN3ME2yMlU4ODF2IN88US=>	M{WyRXNCVkeHUh?=
786-0	M1\Ne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfNTWM2OD1{LkW5NlM5KM7:TR?=	NGjpXlVUSU6JRWK=
SKG-IIIa	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\qVZBKSzVyPUKuOlU6OzlizszN	NH\iSpVUSU6JRWK=
MEL-HO	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLwPXBLUUN3ME2yMlY4PjN2IN88US=>	Mn\xV2FPT0WU
LCLC-97TM1	NIexTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHyWJJVUUN3ME2yMlY6OjZ5IN88US=>	NEGwUpRUSU6JRWK=
MKN7	MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHpb3B2UUN3ME2yMlcxPzV2IN88US=>	MkjVV2FPT0WU
5637	MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2K3UWlEPTB;Mj63NVA{PSEQvF2=	M1XqbXNCVkeHUh?=
HOP-92	M3zXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1X4RWlEPTB;Mj63OFcyPyEQvF2=	MnXoV2FPT0WU
MDA-MB-157	NUjCUnBGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjtS3R7UUN3ME2yMlgzODJ\|IN88US=>	M3XKRXNCVkeHUh?=
NB12	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDhc2VmUUN3ME2yMlg1QTF2IN88US=>	MnP0V2FPT0WU
DMS-273	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU[0cYdKUUN3ME2yMlg3PDdizszN	MlTJV2FPT0WU
HCC70	M3\mb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHHTWM2OD1{Lki2OVg6KM7:TR?=	NEjR[VdUSU6JRWK=
YKG-1	NGTOZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPtTWM2OD1\|LkCzO\|g4KM7:TR?=	NES5cXRUSU6JRWK=
NCI-H28	M2GwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGL1TIlKSzVyPUOuNFUzQTFizszN	NYTJVHZiW0GQR1XS
HN	M2e3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTNwME[2N\|Yh\|ryP	NUXXdWh[W0GQR1XS
HT-1080	NU[zSldWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTNwMEi2NFYh\|ryP	M2jlSHNCVkeHUh?=
HPAF-II	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\rTWM2OD1\|LkGwNFY5KM7:TR?=	MUPTRW5ITVJ?
U-2-OS	MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTNwMUO3PFIh\|ryP	M2exVnNCVkeHUh?=
SNU-387	Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTNwMU[zOlQh\|ryP	MkXWV2FPT0WU
Becker	M{L3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LCT2lEPTB;Mz6xOlgxQCEQvF2=	NEHGfZFUSU6JRWK=
BHY	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTMTWM2OD1\|LkK1OVcyKM7:TR?=	NV6wb2MzW0GQR1XS
HTC-C3	NFLpOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rH[WlEPTB;Mz6yPVM2OiEQvF2=	MmLWV2FPT0WU
M14	MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTNwM{C2OlMh\|ryP	NG\ISZpUSU6JRWK=
COR-L23	M4nHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTNwM{eyO\|kh\|ryP	NUTIbnNVW0GQR1XS
C32	NYC4WXJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLrTWM2OD1\|LkSxOVA5KM7:TR?=	NVzVTVNJW0GQR1XS
Mewo	NUHH[Gs4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYWydoU4UUN3ME2zMlQzOTh{IN88US=>	NWC3V5J7W0GQR1XS
TE-8	MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTNwNEiyOVkh\|ryP	NID2fJNUSU6JRWK=
RPMI-2650	MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTyTWM2OD1\|Lk[wOlM4KM7:TR?=	Ml3kV2FPT0WU
AGS	M1vWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnPe25NUUN3ME2zMlYzPDZ2IN88US=>	NVzaSGt6W0GQR1XS
MZ2-MEL	MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jFPWlEPTB;Mz62OlE{QCEQvF2=	MVvTRW5ITVJ?
Calu-3	MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7xTWM2OD1\|LkexNlg4KM7:TR?=	MmHQV2FPT0WU
SJSA-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrsfHZ6UUN3ME2zMlcyOzF3IN88US=>	MmSyV2FPT0WU
SW962	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4myVWlEPTB;Mz63NlY{PiEQvF2=	NIrGcGlUSU6JRWK=
PC-14	M4\SXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTNwN{OyNlIh\|ryP	MXrTRW5ITVJ?
SW1573	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWD6fmw1UUN3ME2zMlc2OzR6IN88US=>	NEC4SXNUSU6JRWK=
769-P	NIDYO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTNwOEK3OFMh\|ryP	MYfTRW5ITVJ?
KNS-62	NIjh[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULsRZc5UUN3ME2zMlkzOzN6IN88US=>	NE\XXWVUSU6JRWK=
NCI-H747	MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTRwMEW2N\|gh\|ryP	NYDsO5A6W0GQR1XS
LN-405	MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTRwMUW3Nlgh\|ryP	M4DIVnNCVkeHUh?=
OVCAR-8	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjzTWM2OD12LkKyOVQ{KM7:TR?=	M{DPeHNCVkeHUh?=
DMS-114	M4LJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3jOI9KSzVyPUSuNlM5QTFizszN	M3\FOXNCVkeHUh?=
NCI-H2126	NUjsUY52T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFP3cJFKSzVyPUSuNlQ2PThizszN	M3fac3NCVkeHUh?=
TCCSUP	MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLEXpVKSzVyPUSuNlQ4QDhizszN	NGXxVGZUSU6JRWK=
SK-N-FI	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGH3OYxKSzVyPUSuNlU{OzJizszN	NES5d5lUSU6JRWK=
HCE-4	M4fMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2[1RWlEPTB;ND6yO\|E6PyEQvF2=	NEfieJhUSU6JRWK=
DK-MG	M1vKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTRwM{CzPUDPxE1?	MWHTRW5ITVJ?
RO82-W-1	NHfEWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXK1eHUxUUN3ME20MlMzPTh2IN88US=>	Mm\XV2FPT0WU
A2780	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nlNmlEPTB;ND6zOlY5OiEQvF2=	MoTXV2FPT0WU
ETK-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXjXWN2UUN3ME20MlM4ODV{IN88US=>	NYfjUW5[W0GQR1XS
FADU	NYLoVnM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\RfGhnUUN3ME20MlM4PDZ5IN88US=>	MmnNV2FPT0WU
CAL-12T	NHGyOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LCdmlEPTB;ND60NVQyOyEQvF2=	MVHTRW5ITVJ?
647-V	MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTKTWM2OD12LkS0NFIzKM7:TR?=	M3;BNnNCVkeHUh?=
TGBC1TKB	NGjSWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTRwNEWxNVMh\|ryP	NWf2[3k2W0GQR1XS
LU-99A	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTRwNE[wOkDPxE1?	MVPTRW5ITVJ?
CAL-33	M{\mfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX:0ZlZSUUN3ME20MlUzPDV4IN88US=>	NFOyeolUSU6JRWK=
LU-134-A	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTRwNUK3OFUh\|ryP	Mnj3V2FPT0WU
NCI-H1355	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV6wbmRJUUN3ME20MlU2OTR4IN88US=>	MX;TRW5ITVJ?
RPMI-7951	NFzheGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVm5c4k{UUN3ME20MlU4ODB{IN88US=>	Ml3sV2FPT0WU
TE-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nFN2lEPTB;ND62OlE1OyEQvF2=	NIOwfXZUSU6JRWK=
OE33	NXzWZldsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPBTWM2OD12LkewOVEyKM7:TR?=	MXPTRW5ITVJ?
CAL-51	MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrrTWM2OD12LkexNFgzKM7:TR?=	NFfWTZlUSU6JRWK=
SW1783	NUHlS\|VbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2G1emlEPTB;ND63OVMxQCEQvF2=	NWPUXo44W0GQR1XS
BT-474	NIKxbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDF[JdyUUN3ME20Mlc3Ozh2IN88US=>	NWXKS3pnW0GQR1XS
KYSE-520	NEHzU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTRwOEezPVIh\|ryP	MmXHV2FPT0WU
8-MG-BA	NUmzNphZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTRwOEi1OVch\|ryP	NV7IZ29NW0GQR1XS
IA-LM	Mon1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHj0TpRKSzVyPUSuPVk1OzVizszN	MUHTRW5ITVJ?
SW954	NHH2TXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnZN4VYUUN3ME20Mlk6PDR\|IN88US=>	MXLTRW5ITVJ?
RPMI-8226	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXT1O5hDUUN3ME21MlA2PDZzIN88US=>	M{W5d3NCVkeHUh?=
MKN1	Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTVwMEe5Nlch\|ryP	MmjVV2FPT0WU
A375	NHO0PG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm[0TWM2OD13LkC5NlU3KM7:TR?=	NH3mclRUSU6JRWK=
8305C	NWHWZZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojuTWM2OD13LkC5PFg4KM7:TR?=	NFX2dXlUSU6JRWK=
CAL-62	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2X1NGlEPTB;NT6xPFI2QSEQvF2=	MnrCV2FPT0WU
NB10	NUjIcYk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\1UWlEPTB;NT6yNlc1PCEQvF2=	NFLQe4dUSU6JRWK=
OC-314	NETD[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTVwM{e0OFQh\|ryP	MVTTRW5ITVJ?
PSN1	MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnK2TWM2OD13LkO4Nlg3KM7:TR?=	NIL4S3RUSU6JRWK=
GR-ST	NULLcWhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTVwM{izNlIh\|ryP	Mn\kV2FPT0WU
P12-ICHIKAWA	NEe2TotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTVwNECxJO69VQ>?	M1PkW3NCVkeHUh?=
NCI-H1092	NYLGclVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTVwNEGxOFgh\|ryP	M2DGPHNCVkeHUh?=
SCC-4	M3L5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXlVo1pUUN3ME21MlQyOzV3IN88US=>	NVrYdZNEW0GQR1XS
TE-6	M4THcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTVwNEG4NVYh\|ryP	Mn;3V2FPT0WU
DOHH-2	NYLJdnZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TKd2lEPTB;NT60NlI1QCEQvF2=	MWLTRW5ITVJ?
SW684	NXLOSlhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDDXIwyUUN3ME21MlY3Ozh3IN88US=>	NED4dVNUSU6JRWK=
CP50-MEL-B	NYP0U3BuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHruTlBKSzVyPUWuOlg3QDRizszN	NHPnTJJUSU6JRWK=
UM-UC-3	NWnYblhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF:4OJBKSzVyPUWuO\|IzOzFizszN	M2fPeXNCVkeHUh?=
LC-2-ad	NHfBXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTVwN{iyOVEh\|ryP	NHPZfGtUSU6JRWK=
PC-3	NUfZSYM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHw[HBOUUN3ME21MlkyPjF3IN88US=>	M3zl[nNCVkeHUh?=
CAN	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MluwTWM2OD13LkmyPFIh\|ryP	M1jTTHNCVkeHUh?=
ESS-1	MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLQd25KSzVyPUWuPVc5PjlizszN	Mn;xV2FPT0WU
ATN-1	M1zsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\BTWM2OD14LkC1OVY5KM7:TR?=	MmK3V2FPT0WU
BxPC-3	NILHZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXB[2xKSzVyPU[uNFgzOTlizszN	MnmzV2FPT0WU
KYSE-150	M2DMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjKTWM2OD14LkGyOFc3KM7:TR?=	NEDBSIRUSU6JRWK=
RPMI-8866	NUfjOpoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPlWXJKSzVyPU[uNVkyPjNizszN	MnXrV2FPT0WU
SW780	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LXdWlEPTB;Nj6yNFQzKM7:TR?=	MV3TRW5ITVJ?
A388	Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlqxTWM2OD14LkKzNVE2KM7:TR?=	MlmyV2FPT0WU
NCI-H1437	MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHQZYh{UUN3ME22MlI1ODd\|IN88US=>	MnO1V2FPT0WU
NCI-H1755	MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTaTWM2OD14LkO2OlEzKM7:TR?=	MYnTRW5ITVJ?
LS-123	M3r4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vpWmlEPTB;Nj60NFUzOSEQvF2=	NYTGTnlPW0GQR1XS
CaR-1	M4fjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTZwNE[zO\|Mh\|ryP	MlnGV2FPT0WU
RT-112	M1rVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjkcYlKSzVyPU[uOlA{OzhizszN	NG[zTXpUSU6JRWK=
CGT	Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXaTWM2OD14LkezOlgyKM7:TR?=	NHrLeINUSU6JRWK=
SW626	MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTZwN{O5OFYh\|ryP	MlPMV2FPT0WU
AsPC-1	NVixV2pYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\PR2lEPTB;Nj63OFUxPyEQvF2=	MXjTRW5ITVJ?
SBC-5	NX3qOG1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7vdXVKSzVyPU[uPVczQTdizszN	M4fPR3NCVkeHUh?=
SF539	NYDlVIk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTZwOUmzN\|Mh\|ryP	NVHpV20xW0GQR1XS
TI-73	Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXQTYdsUUN3ME23MlA3Ojh3IN88US=>	MnniV2FPT0WU
MHH-ES-1	NHfFPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTdwMEe3OlIh\|ryP	M{TmSHNCVkeHUh?=
KYSE-510	M1H0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTdwMEi0N\|Ih\|ryP	MXnTRW5ITVJ?
EW-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHMTWM2OD15LkO2PVk3KM7:TR?=	MUPTRW5ITVJ?
SK-OV-3	Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDwb2VKSzVyPUeuN\|k1OzJizszN	NEHac5RUSU6JRWK=
MC-IXC	NVTyWnZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrvTWM2OD15LkSxPVczKM7:TR?=	MYfTRW5ITVJ?
HSC-2	NWjPUplET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTGU21UUUN3ME23MlQzPzB3IN88US=>	NH\XS45USU6JRWK=
NCI-H2342	M2rKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEC1NXFKSzVyPUeuOVE1QSEQvF2=	Mn3KV2FPT0WU
NCI-H1792	M4D0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjacld5UUN3ME23MlUyPzFzIN88US=>	M1HYVHNCVkeHUh?=
HT-1376	NYTkS3dIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvXTWM2OD15Lki3O\|c5KM7:TR?=	MlnzV2FPT0WU
EW-13	M2Xpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTa[\|h2UUN3ME23Mlg6QTd5IN88US=>	MkLtV2FPT0WU
no-11	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPXNZRKSzVyPUeuPVAyPzRizszN	NXK0SphZW0GQR1XS
Daoy	MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\NR2lEPTB;Nz65OFMzOSEQvF2=	MoH0V2FPT0WU
COLO-800	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzrVXNsUUN3ME24MlA1OTZ{IN88US=>	MkjIV2FPT0WU
GB-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2D2ZWlEPTB;OD6wOlU3PSEQvF2=	NUHTbm5qW0GQR1XS
SJRH30	NY\1T\|N5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRThwMUW4O\|gh\|ryP	NV3OXpVSW0GQR1XS
NCI-H2291	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRThwMkmxPFch\|ryP	Mn3WV2FPT0WU
J82	MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\hbmlEPTB;OD6yPVQ6OSEQvF2=	NUG5ZZY4W0GQR1XS
NCI-H596	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\jRXNKSzVyPUiuN\|E1PTNizszN	NHPUdpRUSU6JRWK=
RERF-LC-MS	M2O3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXYTWM2OD16LkO0PFU3KM7:TR?=	NWDXe5RxW0GQR1XS
RH-18	NVPWVZVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojSTWM2OD16LkO1NFQ3KM7:TR?=	MUPTRW5ITVJ?
SW48	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRThwNUm0OVMh\|ryP	M4q3cXNCVkeHUh?=
RD	M3HDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDhTWM2OD16LkW5N\|kyKM7:TR?=	MkXFV2FPT0WU
MS-1	NYqySYR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17xNWlEPTB;OD62NVM5PyEQvF2=	M4rGSnNCVkeHUh?=
ES6	MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRThwN{OxNVkh\|ryP	M3q0WnNCVkeHUh?=
TE-12	NFrCe2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnqOZFZUUN3ME24Mlc4PTB3IN88US=>	NInF[ZFUSU6JRWK=
DBTRG-05MG	MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHK4NZVKSzVyPUiuPVEzOTdizszN	NIO5XFFUSU6JRWK=
KINGS-1	NITpW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlT0TWM2OD16LkmyPVM5KM7:TR?=	Ml3vV2FPT0WU
HLE	NWrLTXFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLjS2dpUUN3ME24Mlk{Pzh3IN88US=>	Mm\WV2FPT0WU
MHH-NB-11	M176ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\qc2pPUUN3ME25MlAyQDN7IN88US=>	Mn7oV2FPT0WU
U-87-MG	NV[wcmtNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEWzToRKSzVyPUmuNlQ{OjFizszN	M1[4ZnNCVkeHUh?=
MN-60	NVTp[XpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTlwMkS1OFIh\|ryP	MVPTRW5ITVJ?
SAS	NUmye2JGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfIWlZKSzVyPUmuNlU2QDFizszN	MYLTRW5ITVJ?
NCI-H446	MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XDTmlEPTB;OT6zOlEh\|ryP	MUnTRW5ITVJ?
C-33-A	MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVuwb\|VkUUN3ME25MlQ{QTh6IN88US=>	MkjOV2FPT0WU
RXF393	NX\Hc21FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLNd2JQUUN3ME25MlQ4ODB{IN88US=>	MWjTRW5ITVJ?
CGTH-W-1	MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXHV2VKSzVyPUmuOFk{QDRizszN	MnvtV2FPT0WU
RCM-1	NYm4T2JsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjtd5ZkUUN3ME25MlY{QDBzIN88US=>	NVzoV4hpW0GQR1XS
SN12C	NH33dWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnf3TWM2OD17Lk[1N\|M5KM7:TR?=	M3rwdXNCVkeHUh?=
KLE	NYnOR3M5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHHTWM2OD17LkewNFA6KM7:TR?=	M2DlVHNCVkeHUh?=
EFO-21	MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrXelFKSzVyPUmuO\|c{QDJizszN	NF;lVHRUSU6JRWK=
KYSE-70	NUL6Z4l4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHPW3hCUUN3ME25Mlg5ODFzIN88US=>	MY\TRW5ITVJ?
D-247MG	NVXLe4R5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;N[IxZUUN3ME2xNE4xPTZ6IN88US=>	NGTDVWpUSU6JRWK=
MPP-89	NIjX[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTFyLkC5OFYh\|ryP	NXjTcWR1W0GQR1XS
RVH-421	NUD2TnNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVe5S4tJUUN3ME2xNE4yPTB3IN88US=>	NYfUSmpDW0GQR1XS
NCI-H460	M3HtTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzre2xKSzVyPUGwMlI5ODZizszN	NELpV5hUSU6JRWK=
NOMO-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTFyLkO1N\|Ih\|ryP	NInnNHRUSU6JRWK=
DEL	NX3mW4FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLmVXpKSzVyPUGwMlM4QTRizszN	Mn\rV2FPT0WU
HT55	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTFyLk[yNFUh\|ryP	NILTU29USU6JRWK=
MC116	M2nOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXQXplXUUN3ME2xNE43PjV3IN88US=>	MX\TRW5ITVJ?
BB30-HNC	NVrne4N{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPhSmV1UUN3ME2xNE43PjlizszN	Mnv5V2FPT0WU
DJM-1	NVS0TmJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MomxTWM2OD1zMD62PVQ6KM7:TR?=	MkfwV2FPT0WU
ZR-75-30	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfGTWM2OD1zMD65OFQyKM7:TR?=	MWHTRW5ITVJ?
U-118-MG	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XC[GlEPTB;MUCuPVg6PiEQvF2=	M1vMfXNCVkeHUh?=
MSTO-211H	M3;hUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nmNmlEPTB;MUGuNFcyPiEQvF2=	MXfTRW5ITVJ?
SW837	NIrhW\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTFzLkC5OFkh\|ryP	M2m2Z3NCVkeHUh?=
HuCCT1	MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rrVmlEPTB;MUGuNVI5OSEQvF2=	NF7hS\|NUSU6JRWK=
RCC10RGB	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFW0d\|VKSzVyPUGxMlE{PSEQvF2=	NHnqN3dUSU6JRWK=
NMC-G1	M{XBSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfLNnU4UUN3ME2xNU4yPDl\|IN88US=>	MnfFV2FPT0WU
NCI-H650	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn63TWM2OD1zMT6zO\|k1KM7:TR?=	NYnQZ\|A3W0GQR1XS
HEC-1	NVX3VY1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXLb4xKSzVyPUGxMlQ{OjhizszN	NGLSdIlUSU6JRWK=
DU-4475	NYTxUmdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzibnBDUUN3ME2xNU44Ozl\|IN88US=>	NIX4XJBUSU6JRWK=
DSH1	NWrQb5B7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLkTWM2OD1zMT63OlA3KM7:TR?=	NH3yUZFUSU6JRWK=
HCC1569	M3;1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjOTWM2OD1zMT63Olc5KM7:TR?=	MWPTRW5ITVJ?
HCC1187	NHnxTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LxdGlEPTB;MUGuPFU5QCEQvF2=	MYfTRW5ITVJ?
EW-11	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlH0TWM2OD1zMT65OFc1KM7:TR?=	MYfTRW5ITVJ?
LB2518-MEL	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXVTWFKSzVyPUGyMlA2QSEQvF2=	NIDjT5BUSU6JRWK=
KALS-1	M1jLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLMWYxyUUN3ME2xNk45PTV\|IN88US=>	NVTPVXE4W0GQR1XS
8505C	MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLnU5d3UUN3ME2xNk45QDVizszN	NUjZZXNWW0GQR1XS
SK-N-DZ	M37r[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M373OWlEPTB;MUOuNFQ2OyEQvF2=	NX;vdIl[W0GQR1XS
CHP-134	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3Jb\|hKSzVyPUGzMlEyPThizszN	M{Pu[XNCVkeHUh?=
HCE-T	NX;rfWQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkOyTWM2OD1zMz6yN\|Y1KM7:TR?=	MWPTRW5ITVJ?
LB-831-BLC	M3HTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVe5RZdRUUN3ME2xN{43OjR4IN88US=>	NES2eYZUSU6JRWK=
OVCAR-4	NWTVWVBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLMTWM2OD1zMz62OVI1KM7:TR?=	NFfyUolUSU6JRWK=
SW756	NX7lb2pNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTF\|LkeyOFYh\|ryP	NV\DV5A4W0GQR1XS
OCUB-M	NUfpfoV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfnbIdKSzVyPUGzMlgyPTZizszN	M2XpTXNCVkeHUh?=
SW982	NEnXeZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfTWYI3UUN3ME2xN{45Ojd4IN88US=>	NUTncG5IW0GQR1XS
DB	MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;FcGlEPTB;MUOuPFM5PCEQvF2=	NUHIeXRQW0GQR1XS
H-EMC-SS	MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHkTWM2OD1zMz65NVM6KM7:TR?=	NHnDSnRUSU6JRWK=
VMRC-RCZ	NInhdnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPMd3hKSzVyPUG0MlAxOTVizszN	NEHxdIxUSU6JRWK=
CAKI-1	NH3oO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPzb4RKSzVyPUG0MlAyOzJizszN	M4TXRnNCVkeHUh?=
GI-1	M{TMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvFTWM2OD1zND6wOlU5KM7:TR?=	NFfQR2pUSU6JRWK=
Ca9-22	NGrid2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTF2Lk[wOVQh\|ryP	NIftUGlUSU6JRWK=
TE-5	NETmWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HGUGlEPTB;MUSuO\|IxQCEQvF2=	MVXTRW5ITVJ?
EFO-27	MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TRT2lEPTB;MUSuO\|YzOiEQvF2=	MYPTRW5ITVJ?
CAL-72	M1nBemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUO4SGFiUUN3ME2xOE44Pzh\|IN88US=>	M4fCNnNCVkeHUh?=
GP5d	NF3xVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvVTWM2OD1zNT6wOFc1KM7:TR?=	MUfTRW5ITVJ?
CAS-1	NHjTZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7PV\|FKUUN3ME2xOU4xPjZizszN	MUXTRW5ITVJ?
A2058	MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF31XVNKSzVyPUG1MlU3OzhizszN	MUfTRW5ITVJ?
PANC-08-13	MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHNTWM2OD1zNT62PFU6KM7:TR?=	M3q3OnNCVkeHUh?=
Detroit562	M2ThN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVO1W4tuUUN3ME2xOU46OTN7IN88US=>	NXLTZoRKW0GQR1XS
PANC-10-05	Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF[3OItKSzVyPUG2MlA5OjFizszN	NVizVZBjW0GQR1XS
KOSC-2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTF4LkGxNlUh\|ryP	MWrTRW5ITVJ?
GT3TKB	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rpc2lEPTB;MU[uNVk5OSEQvF2=	NXXYSI9NW0GQR1XS
KM-H2	MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzMd2NmUUN3ME2xOk4{PjR4IN88US=>	Mlm1V2FPT0WU
LB771-HNC	MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTF4LkS0NlIh\|ryP	NX35Uo9MW0GQR1XS
SF268	MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTIfm1JUUN3ME2xOk41PTJizszN	M1TCN3NCVkeHUh?=
OE19	M4rYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTF4LkWyOEDPxE1?	NIHxWo9USU6JRWK=
MLMA	NHzhR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTF4LkW1O\|Eh\|ryP	NHvsbVFUSU6JRWK=
MDA-MB-231	NXHyc4xRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Tqc2lEPTB;MU[uO\|E{PiEQvF2=	MnKwV2FPT0WU
TGW	M1Kzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\tT4xKSzVyPUG2MlgyODJizszN	NY\SbpM6W0GQR1XS
MDA-MB-453	NU\6OnEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7iTWM2OD1zNz6wNFA{KM7:TR?=	MU\TRW5ITVJ?
SNU-C2B	NGHiRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFz3[ZRKSzVyPUG3MlAzOzdizszN	NFLBfoZUSU6JRWK=
A427	NWPKfpRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{S1dWlEPTB;MUeuNlM{PCEQvF2=	MV;TRW5ITVJ?
SK-MEL-2	M{jG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTF5LkOyNVMh\|ryP	MVzTRW5ITVJ?
KURAMOCHI	NIfJfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HDdmlEPTB;MUeuN\|g6PyEQvF2=	MV;TRW5ITVJ?
IST-MEL1	NF;aemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvzRnZKSzVyPUG3MlkyQDJizszN	NYLwflk3W0GQR1XS
NCI-H1793	MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTF6LkG1PFEh\|ryP	NWjjc4liW0GQR1XS
HCC1395	M2jDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGH2TW9KSzVyPUG4MlU3OTFizszN	Mkm0V2FPT0WU
NUGC-3	MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jEUGlEPTB;MUiuOlU5PCEQvF2=	NGHE[XZUSU6JRWK=
BB65-RCC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPPTWM2OD1zOD62Olkh\|ryP	MonHV2FPT0WU
RMG-I	NGPFXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLHOpJKSzVyPUG4Mlc{QDJizszN	MXjTRW5ITVJ?
LS-513	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fUTmlEPTB;MUiuPVIzQCEQvF2=	NYKyNZNEW0GQR1XS
MFM-223	NGDP[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DqVWlEPTB;MUmuNFcyPiEQvF2=	M1jpbXNCVkeHUh?=
NCI-H727	NIjWTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TyV2lEPTB;MUmuN\|I6PSEQvF2=	MWfTRW5ITVJ?
KP-4	NVTmeXU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTF7Lki1N\|Eh\|ryP	NWjwPY1NW0GQR1XS
NB13	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3wenRKSzVyPUG5Mlg5OzlizszN	NEPkWIVUSU6JRWK=
UACC-893	M3nEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTF7Lkm3OVch\|ryP	MWjTRW5ITVJ?
HT-1197	NYOz[lA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfEVoNKSzVyPUKwMlI6PThizszN	NWflXlV6W0GQR1XS
NCI-H2029	MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTJyLkOyOlYh\|ryP	NXS4WJNjW0GQR1XS
GI-ME-N	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XSS2lEPTB;MkCuN\|M4OyEQvF2=	NHv3VHVUSU6JRWK=
OVCAR-3	NWq0OFBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHuTWM2OD1{MD61PFIzKM7:TR?=	NIrjZ3pUSU6JRWK=
HD-MY-Z	MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;BNWlEPTB;MkGuN\|Y6PiEQvF2=	MofVV2FPT0WU
NTERA-S-cl-D1	M{jSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTJzLk[3NlIh\|ryP	MlGzV2FPT0WU
SCH	NV;NTGM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLaOYZMUUN3ME2yNk41QTZizszN	NXfqdpdRW0GQR1XS
KARPAS-299	M1zLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvhTWM2OD1{Mz6zPFg4KM7:TR?=	NIHkWHRUSU6JRWK=
NCI-H1650	NWnKR29wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmX5TWM2OD1{Mz65NlQyKM7:TR?=	Mln4V2FPT0WU
ACHN	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XVN2lEPTB;MkSuOFY2PiEQvF2=	NHjpU5NUSU6JRWK=
M059J	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1X2fmlEPTB;MkSuOVY{PCEQvF2=	NHXobpZUSU6JRWK=
AM-38	NVvh[mZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLPTWM2OD1{NT60PFEh\|ryP	NVHkZW9KW0GQR1XS
KG-1	M1LRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33pO2lEPTB;MkWuOVQ6PCEQvF2=	NETLcWVUSU6JRWK=
COLO-824	NGDROHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELyR2FKSzVyPUK1MlU2QTlizszN	NFrn[W9USU6JRWK=
NCI-H1155	M17QWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7mTWM2OD1{NT61PFQ4KM7:TR?=	MULTRW5ITVJ?
NCI-H441	MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjSU2tKSzVyPUK1Mlc1PjVizszN	MVjTRW5ITVJ?
J-RT3-T3-5	NXTw[2d1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE[5[nNKSzVyPUK2MlMxOjdizszN	MmjoV2FPT0WU
JEG-3	MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTJ4Lk[4NFUh\|ryP	NE\4UoZUSU6JRWK=
RKO	Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTJ4Lke2N\|Ih\|ryP	MXvTRW5ITVJ?
CAL-85-1	MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPLelNKSzVyPUK3MlIyOThizszN	MmP5V2FPT0WU
CAL-120	MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPSTWM2OD1{Nz62PVE1KM7:TR?=	MV3TRW5ITVJ?
NCI-H2452	Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfOTWM2OD1{Nz63O\|E3KM7:TR?=	Mn3YV2FPT0WU
NCI-H1395	NXL1bYdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DRS2lEPTB;MkeuO\|g{OyEQvF2=	NUe2emVYW0GQR1XS
KYSE-450	M1vzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV2yXFIzUUN3ME2yO{46QDZ{IN88US=>	MUfTRW5ITVJ?
S-117	NIruboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrzbYRYUUN3ME2yPU4{QDV5IN88US=>	NYjReXhVW0GQR1XS
SW13	NIjIdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXj[FJKSzVyPUK5Mlg2OTlizszN	NXzwZ5ZpW0GQR1XS
ES3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLxWJlKSzVyPUOwMlM4OzNizszN	MY\TRW5ITVJ?
HCT-116	NH3lco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jObGlEPTB;M{CuOVU2PCEQvF2=	NHrXc3NUSU6JRWK=
NCI-H1693	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTNyLkW5OFIh\|ryP	NY\0e3dkW0GQR1XS
VM-CUB-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDEeoJKSzVyPUOwMlY1OTNizszN	MojYV2FPT0WU
NCI-H2170	M3;HO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGq3[IVKSzVyPUOxMlU4QDRizszN	MmjPV2FPT0WU
ALL-PO	MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTNzLki0Nlgh\|ryP	M2juOHNCVkeHUh?=
NCI-H661	MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEL6ZXdKSzVyPUOyMlA3OjNizszN	M3fhU3NCVkeHUh?=
NCI-H2347	NIrqb\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYm5cY5qUUN3ME2zNk41QDN5IN88US=>	NVfVclM2W0GQR1XS
FTC-133	NYHEdWRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Czb2lEPTB;M{KuO\|A3KM7:TR?=	M17KNXNCVkeHUh?=
COLO-829	MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTN\|LkO0Olch\|ryP	MmnGV2FPT0WU
GOTO	NFjJNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rRWWlEPTB;M{OuOVI2QCEQvF2=	NHHNN3RUSU6JRWK=
YAPC	NXfwPJdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEn6d3JKSzVyPUOzMlgyPTlizszN	NUPCS2dZW0GQR1XS
LCLC-103H	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknMTWM2OD1\|ND6xOlI1KM7:TR?=	MkPUV2FPT0WU
SiHa	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4m3cGlEPTB;M{SuN\|gyPyEQvF2=	M2K5UnNCVkeHUh?=
LK-2	NI[xXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfHfoJKSzVyPUO0MlU4ODhizszN	MVTTRW5ITVJ?
KP-N-YS	NWTHeIFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTN2LkeyNFIh\|ryP	MVXTRW5ITVJ?
NCI-SNU-1	NF\MU\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2q4c2lEPTB;M{WuNVc6KM7:TR?=	MnPZV2FPT0WU
KNS-81-FD	MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGf0coVKSzVyPUO1MlY3OyEQvF2=	MX3TRW5ITVJ?
SCC-9	M4G1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvIOmxKSzVyPUO2MlcyPDZizszN	NFjHdmtUSU6JRWK=
SH-4	MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfnbnNKSzVyPUO2Mlc{KM7:TR?=	NWn5S3lyW0GQR1XS
HCC-1954	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIn4cohKSzVyPUO3MlI4OjlizszN	NXPQSZc4W0GQR1XS
BALL-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTN5LkWzNVYh\|ryP	NHG4VZhUSU6JRWK=
BE-13	MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\FeFhKSzVyPUO3MlcxOThizszN	M3jIWHNCVkeHUh?=
COLO-678	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTN5Lkm0N\|ch\|ryP	M1Hs[nNCVkeHUh?=
SK-MEL-3	M3LIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;W[4ZNUUN3ME2zPE4zOzl5IN88US=>	Mlz1V2FPT0WU
OAW-28	NIXr[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHvVotKSzVyPUO4MlY{QSEQvF2=	M33pVHNCVkeHUh?=
CAMA-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;CeJMyUUN3ME2zPE46PjlzIN88US=>	NIf2NHFUSU6JRWK=
C2BBe1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPGVYdKSzVyPUO5MlgyQCEQvF2=	MnnJV2FPT0WU
A3-KAW	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTRyLkO2OlEh\|ryP	NFzEV4NUSU6JRWK=
SK-MEL-24	NYLIWWFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfFTWM2OD12MD61PVMyKM7:TR?=	NFL1UZFUSU6JRWK=
KYSE-140	NE\ncllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2W0TWlEPTB;NECuO\|E3PSEQvF2=	NWH1OWxEW0GQR1XS
MOLT-16	M3PIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\hNnRPUUN3ME20NU4yPTN4IN88US=>	NWnpfYJqW0GQR1XS
CFPAC-1	Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmX6TWM2OD12Mj61NlEyKM7:TR?=	MUnTRW5ITVJ?
NB14	M3H1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXmTWM2OD12Mj63NFI4KM7:TR?=	M3XQeXNCVkeHUh?=
COLO-792	NHrve3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTR{Lki5OlEh\|ryP	MUfTRW5ITVJ?
RH-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrvb3pvUUN3ME20N{41QDN4IN88US=>	Ml7qV2FPT0WU
NCI-H522	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;1NW5KSzVyPUS0MlM2PjhizszN	NFv2SY5USU6JRWK=
Ca-Ski	NV;3U25bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPRTWM2OD12ND64NVE1KM7:TR?=	Ml\IV2FPT0WU
KGN	NFuwV\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fIbGlEPTB;NEiuN\|A3OyEQvF2=	Mn3GV2FPT0WU
UACC-62	Mo\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTR6LkSwO\|Ih\|ryP	NUK1T41iW0GQR1XS
NCI-H358	M3ey[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPZcWRmUUN3ME20PU4{ODF6IN88US=>	MVHTRW5ITVJ?
LS-411N	MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTqXpd1UUN3ME20PU4{OTF6IN88US=>	MXLTRW5ITVJ?
IST-MES1	NVrmTJVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLlTWM2OD12OT61OlI2KM7:TR?=	MX\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-FoxO3a / FoxO3a / PUMA; PubMed: 29137323 Oncotarget HCT116 cells were treated with 4μmol/L NVP-BKM120 or 4μmol/L Pictilisib for 24 hours. Indicated protein levels were analyzed by Western blotting. p-S6RP / S6RP; PubMed: 30042442 Cell Death Dis Western blot analysis of proteins as indicated in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. Vinculin was used as a loading control. p-4EBP1 / 4EBP1; PubMed: 25857298 Oncotarget Cells were treated with 0.5 μM GDC-0941 for the indicated time course and then collected for Western blot analysis of p-4EBP1. p-LRP6 / LRP6; PubMed: 25857298 Oncotarget MDAMB-231, HCC1937 and MCF7 cells were treated with 0.5 µM GDC-0941 for 1 hr, and cell lysates were used for immunoblot analyses. p-PAK / PAK1 / p-CRAF / RAF / p-MEK / MEK / p-ERK / ERK; PubMed: 24327733 Proc Natl Acad Sci U S A Cells were treated with 1 μM GDC-0941 for the indicated times, and lysates were probed with the indicated antibodies. Independent experiments were performed at least three times, and a representative result is shown.	29137323 30042442 25857298 24327733
Immunofluorescence	p65; PubMed: 30042442 Cell Death Dis Representative images of immunofluorescent staining of p65 cellular localization in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. 4T1 cells were cultured alone or co-cultured with RAW264.7 macrophages. Representative images of three independent experiments are shown. beta-catenin; PubMed: 25857298 Oncotarget Cells were seeded on coverslips the day before the experiment and treated with 0.5 µM GDC-0941 for 18 hr. The immunofluorescence (IF) of beta-catenin is indicated as red fluorescence, and double staining with DAPI is blue. Magnification: 400 X for the left three panels. The right panel shows enlarged images from the white squares.	30042442 25857298
Growth inhibition assay	Cell viability; PubMed: 27117832 J Thorac Oncol The viability of the indicated cells treated with increasing concentrations of GDC-0941 (ranging from 70nM to 20 μM) for 72 hours, determined by CellTiter Glo Viability assay. The IC50 concentrations were calculated using GraphPad Prism program. The assay was performed in triplicate, and the error bars represent standard deviations.	27117832

In vivo

GDC-0941 shows limited microsomal metabolism, resulting in 78% oral bioavailability ^[5]. Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. ^[1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. ^[2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Scintillation proximity assay: Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl₂, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-³³P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.
Cell Research: ^[2]	- Collapse Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 48 and 72 hours Method: Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISA^plus assay are used to detect caspase 3/7 activity, and apoptosis, respectively. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdc^scid mice implanted subcutaneously with BT474-M1 cells Dosages: ~150 mg/kg/day Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	44 mg/mL (85.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Pictilisib (GDC-0941) SDF

Molecular Weight	513.64
Formula	C₂₃H₂₇N₇O₃S₂
CAS No.	957054-30-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	RG7321
Smiles	C[S](=O)(=O)N1CCN(CC1)CC2=CC3=NC(=NC(=C3S2)N4CCOCC4)C5=CC=CC6=C5C=N[NH]6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02092831	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	April 2014	Phase 1
NCT01740336	Completed	Drug: GDC-0941\|Drug: Placebo\|Drug: Paclitaxel	Breast Cancer	Genentech Inc.	February 6 2013	Phase 2
NCT01474668	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	October 2011	Phase 1
NCT01240226	Completed	Drug: GDC-0941\|Drug: ketoconazole	Healthy Volunteer	Genentech Inc.	November 2010	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Pan PI3K Inhibitor

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)